Finance

Beta
Lists
9EP:FRA
Enanta Pharmaceuticals Inc
€10.20
+3.55%
(+0.35) 1D
Jun 12, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 9EP...
Open
€9.70
High
€10.30
Low
€9.20
Mkt. cap
346.03M
Avg. vol.
14.00
Volume
0.00
52-wk high
€14.20
52-wk low
€5.45
No. of employees
120
Open
€9.70
High
€10.30
Low
€9.20
Mkt. cap
346.03M
Avg. vol.
14.00
Volume
0.00
52-wk high
€14.20
52-wk low
€5.45
No. of employees
120
News stories
From sources across the web
About Enanta Pharmaceuticals Inc
CEO-
Employees120
Founded1995
HeadquartersWatertown, Massachusetts, United States
SectorBiotechnology
Websiteenanta.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.31M
15.12M
18.62M
17.16M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.21M
23.81M
20.86M
19.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.00M
9.70M
9.01M
9.57M
Operating expense
37.21M
33.51M
29.87M
29.01M
Total operating expenses
37.21M
33.51M
29.87M
29.01M
Operating income
-18.89M
-18.39M
-11.25M
-11.85M
Other non operating income
-
39.00K
-
-
EBT including unusual items
-18.23M
-18.67M
-11.91M
-13.08M
EBT excluding unusual items
-18.23M
-19.63M
-11.89M
-13.08M
Income tax expense
29.00K
32.00K
24.00K
7.00K
Effective tax rate
-0.16%
-0.17%
-0.20%
-0.05%
Other operating expenses
-
-
-
-
Net income
-18.26M
-18.70M
-11.94M
-13.09M
Net profit margin
-99.68%
-123.64%
-64.13%
-76.29%
Earnings per share
-0.85
-0.87
-0.42
-0.45
Interest and investment income
2.28M
1.11M
2.44M
2.08M
Interest expense
-1.62M
-2.39M
-3.08M
-3.32M
Net interest expenses
667.00K
-1.28M
-641.00K
-1.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.68M
-17.10M
-10.02M
-10.64M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer